Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Phase 1

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: Pasireotide LAR

First Posted Date: 2011-06-02

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT01364415

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute SC-1, Tampa, Florida, United States
🇺🇸
Dana Farber Cancer Institute SC-6, Boston, Massachusetts, United States
🇺🇸
Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States

and more 1 locations

A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

Phase 2

Terminated

Conditions: Polymyalgia Rheumatica
Inflammatory Diseases

Interventions: Drug: AIN457
Drug: ACZ885
Drug: Prednisone
Drug: Placebo

First Posted Date: 2011-06-02

Last Posted Date: 2021-09-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT01364389

Locations: 🇬🇧
Novartis Investigative Site, Westcliff-on-Sea, Essex, United Kingdom

Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective

Phase 3

Terminated

Conditions: Gouty Arthritis

Interventions: Drug: Canakinumab, ACZ885
Drug: Triamcinolone acetonide

First Posted Date: 2011-05-30

Last Posted Date: 2017-06-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 136

Registration Number: NCT01362608

Locations: 🇸🇬
Novartis Investigative Site, Singapore, Singapore

Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma

Completed

Conditions: Moderate to Severe Allergic Asthma

First Posted Date: 2011-05-30

Last Posted Date: 2011-06-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 474

Registration Number: NCT01362621

Locations: 🇵🇷
Novartis Investigative Site, San Juan, Puerto Rico

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: secukinumab (AIN457)
Drug: placebo

First Posted Date: 2011-05-25

Last Posted Date: 2015-03-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 221

Registration Number: NCT01359943

Locations: 🇸🇰
Novartis Investigative Site, Topolcany, Slovakia

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Secukinumab (75 mg)
Drug: Secukinumab (150 mg)
Drug: Placebo

First Posted Date: 2011-05-23

Last Posted Date: 2017-03-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 371

Registration Number: NCT01358175

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Phase 3

Completed

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: Placebo
Drug: secukinumab (AIN457)
Drug: etanercept

First Posted Date: 2011-05-23

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1306

Registration Number: NCT01358578

Locations: 🇬🇧
Novartis Investigative Site, Nuneaton, United Kingdom

Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: vildagliptin

First Posted Date: 2011-05-20

Last Posted Date: 2014-04-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 279

Registration Number: NCT01357252

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome

Phase 2

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: AFQ056
Drug: Placebo

First Posted Date: 2011-05-20

Last Posted Date: 2015-05-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 139

Registration Number: NCT01357239

Locations: 🇬🇧
Novartis Investigative Site, Edinburgh, United Kingdom

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Phase 3

Completed

Conditions: Acute Gouty Arthritis

Interventions: Drug: Canakinumab lyophilized powder
Drug: Canakinumab pre-filled syringe
Drug: Triamcinolone Acetonide
Drug: Placebo

First Posted Date: 2011-05-19

Last Posted Date: 2014-01-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 397

Registration Number: NCT01356602

Locations: 🇱🇹
Novartis Investigative Site, Vilnius, Lithuania

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy